BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• 

  Giulia Balconi

  Giulia Balconi, M.P.H., supports research efforts at Adjuvant Capital, an impact investment firm financing life sciences technology companies focused on historically neglected diseases and maternal/child health.
• 

  Apnimed
• 

  Career Advice

  11 Signs of Good Company Culture

  Good company culture is a crucial aspect of professional life. Look at these 11 important indications of good workplace culture before accepting a job offer or use them to evaluate your new employer.

  September 19, 2024

   · 

  4 min read

   · 

  Editorial Staff
• 

  Career Advice

  Evaluating Job Security in a Tough Biopharma Market

  Job security is a hot topic among biopharma professionals. A career coach offers advice for how to evaluate and build it up and what to do if that evaluation leaves you worried.

  September 19, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Vaccines

  GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data

  If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.

  September 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Complete response letters

  Vanda Contests FDA Rejection of Gastroparesis Drug, Slams ‘Delayed’ Decision

  Vanda Pharmaceuticals on Thursday announced that the regulator declined to approve its application, a decision the company says was delayed by more than 185 days and failed to satisfy the requirements of the Federal Drug and Cosmetic Act.

  September 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  After Fed Rate Cut, Biotech Stocks Face ‘Anticlimactic’ Reality

  The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change in the near term.

  September 19, 2024

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Gene therapy

  4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies

  4D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for annualized standard-of-care injections in patients with wet age-related macular degeneration.

  September 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  AstraZeneca Wins Rare Autoimmune Indication for Asthma Biologic Fasenra

  With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.

  September 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  First cases using Smith+Nephew’s new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility

  September 19, 2024

   · 

  6 min read